Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Double trouble for Incyte in KRAS
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
CytomX emerges from masked obscurity
But now it must show that varseta-M can move into a registrational trial.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
The month ahead: March’s upcoming events
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
ASCO-GU – Flare hits an “undruggable” target
But biomarker enrichment and toxicity remain key for FX-909.
